<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974022</url>
  </required_header>
  <id_info>
    <org_study_id>DZ2019E0001</org_study_id>
    <nct_id>NCT03974022</nct_id>
  </id_info>
  <brief_title>Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)</brief_title>
  <official_title>A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dizal Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dizal Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have&#xD;
      progressed following prior therapy. This is the first time this drug is tested in patients,&#xD;
      and so it will help to understand what type of side effects may occur with the drug&#xD;
      treatment. It will also measure the levels of drug in the body and preliminarily assess its&#xD;
      anti-cancer activity as monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability,&#xD;
      Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell&#xD;
      Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation, dose&#xD;
      expansion, food effect (Part A) and dose extension (Part B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Safety and tolerability of DZD9008.</measure>
    <time_frame>28 days after the first multiple dose</time_frame>
    <description>To investigate the safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC with EGFR or HER2 mutations; To establish Maximum Tolerated Dose (MTD) (if possible) and Recommended Phase 2 Dose (PR2D) of DZD9008 when given orally in patients with advanced NSCLC with EGFR or HER2 mutations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Objective Response Rate (ORR) according to RECIST 1.1.</measure>
    <time_frame>through the study completion, an average of around 1 year</time_frame>
    <description>To evaluate anti-tumor activity of DZD9008 in advanced NSCLC patients with EGFR Exon20 insertion, HER2 Exon20 insertion or EGFR uncommon mutations at defined dose(s) (Part B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma DZD9008 concentration</measure>
    <time_frame>Through cycle 3 day 1 (8 days for Cycle 0, 28 days for Cycle 1, then 21 days for each subsequent cycle)</time_frame>
    <description>To characterize the pharmacokinetics (PK) of DZD9008 following a single oral dosing and at steady state after multiple oral dosing, and renal excretion of DZD9008</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>NonSmall Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>DZD9008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DZD9008</intervention_name>
    <description>Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.</description>
    <arm_group_label>DZD9008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged at least 18 years old (≥ 20 if in Japan), be able to provide a signed and dated,&#xD;
             written informed consent.&#xD;
&#xD;
          2. With documented histological or cytological confirmed locally advanced or metastatic&#xD;
             NSCLC with EGFR or HER2 mutations.&#xD;
&#xD;
          3. (ECOG) performance status 0-1.&#xD;
&#xD;
          4. Predicted life expectancy ≥ 12 weeks&#xD;
&#xD;
          5. Patient must have measurable disease according to RECIST 1.1.&#xD;
&#xD;
          6. Patients with brain metastasis (BM) can be enrolled under the condition that BM is&#xD;
             stable, neurologically asymptomatic and does not require corticosteroid treatment.&#xD;
&#xD;
          7. Adequate organ system function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. For part B: Patients who have received prior treatment with Poziotinib or TAK788 or&#xD;
             other EGFR/HER2 exon20 insertion inhibitors should be excluded. Prior treatment with&#xD;
             currently approved EGFR TKIs for sensitizing or T790M resistance mutations, such as&#xD;
             gefitinib, erlotinib, osimertinib, afatinib and dacomitinb, are allowed.&#xD;
&#xD;
          2. Treatment with EGFR or HER2 antibodies, major surgery (excluding placement of vascular&#xD;
             access), or onco-immunotherapy (e.g. immune checkpoint inhibitors PD-1, PD-L1, CTLA-4)&#xD;
             within 4 weeks before screening.&#xD;
&#xD;
          3. Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from a&#xD;
             previous treatment regimen or clinical study within 14 days before screening.&#xD;
&#xD;
          4. Radiotherapy with a limited field of radiation for palliation within 1 week of the&#xD;
             first dose or with a wide field of radiation which must be completed within 4 weeks&#xD;
             before screening.&#xD;
&#xD;
          5. Receiving (or unable to stop using) medications or herbal supplements known to be&#xD;
             potent inhibitors or inducers of CYP3A within 2-3 weeks before screening.&#xD;
&#xD;
          6. Grapefruit, grapefruit juice, and orange marmalade (made with Seville oranges) within&#xD;
             1 week before screening.&#xD;
&#xD;
          7. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of&#xD;
             starting DZD9008 with the exception of alopecia and grade 2 prior platinum-therapy&#xD;
             related neuropathy.&#xD;
&#xD;
          8. Spinal cord compression or leptomeningeal metastasis.&#xD;
&#xD;
          9. As judged by the investigator, any evidence of severe or uncontrolled systemic&#xD;
             diseases, which would jeopardize compliance with the protocol, or active infection&#xD;
             including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).&#xD;
&#xD;
         10. Any of the following cardiac criteria: (1) Mean resting corrected QT interval (QTcF) &gt;&#xD;
             470 msec obtained from 3 electrocardiograms (ECGs); (2) Any clinically significant&#xD;
             abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left&#xD;
             bundle branch block, third degree heart block, and second-degree heart block, PR&#xD;
             interval &gt; 250 msec. (3) Any factors that increase the risk of QTcF prolongation, such&#xD;
             as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT&#xD;
             syndrome or unexplained sudden death under 40 years of age in first degree relatives&#xD;
             or any concomitant medication known to prolong the QT interval&#xD;
&#xD;
         11. Past medical history of interstitial lung disease, drug-induced interstitial lung&#xD;
             disease, radiation pneumonitis which required steroid treatment, or any evidence of&#xD;
             clinically active interstitial lung disease&#xD;
&#xD;
         12. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the formulated product or previous significant bowel resection that would&#xD;
             preclude adequate absorption of DZD9008&#xD;
&#xD;
         13. History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with&#xD;
             a similar chemical structure or class to DZD9008&#xD;
&#xD;
         14. Women who are pregnant or breast feeding&#xD;
&#xD;
         15. Involvement in the planning and conduct of the study.&#xD;
&#xD;
         16. Judgment by the investigator that the patient should not participate in the study if&#xD;
             the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi Antero Janne, M.D &amp; Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zheng, M.D &amp; Ph. D</last_name>
    <phone>86-21-61097899</phone>
    <email>li.zheng@dizalpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Yang, M.D &amp; Ph. D</last_name>
    <phone>86-21-61097866</phone>
    <email>pamela.yang@dizalpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) - Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bazhenova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ross</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janne</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doroshow</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - East Melbourne</name>
      <address>
        <city>North Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Cancer trials</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Millward</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brungs</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital, Liouying</name>
      <address>
        <city>Liuying</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NonSmall Cell Lung Cancer</keyword>
  <keyword>EGFR</keyword>
  <keyword>HER2</keyword>
  <keyword>mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

